trending Market Intelligence /marketintelligence/en/news-insights/trending/cx4dj-cgq1jp8egq5-gqnw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Cellectar treatment secures US FDA orphan drug status for neuroblastoma

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Cellectar treatment secures US FDA orphan drug status for neuroblastoma

Cellectar Biosciences Inc. said its lead compound CLR 131 received the U.S. Food and Drug Administration's orphan drug designation to treat a rare type of cancer in children.

The Madison, Wis.-based biotechnology is studying the medicine as a treatment for neuroblastoma, a cancer that forms in certain types of nerve tissue.

The designation will help provide seven years of market exclusivity once the drug is commercialized as well as other benefits to expedite development.

The drug is also being studied in other indications, including multiple myeloma.